{"id":"indisetron","rwe":[{"pmid":"23364217","year":"2012","title":"Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.","finding":"","journal":"Chemotherapy","studyType":"Clinical Study"},{"pmid":"19967488","year":"2009","title":"Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.","finding":"","journal":"International journal of clinical oncology","studyType":"Clinical Study"},{"pmid":"19755818","year":"2009","title":"[The efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting for lung cancer].","finding":"","journal":"Gan to kagaku ryoho. Cancer & chemotherapy","studyType":"Clinical Study"},{"pmid":"18633256","year":"2008","title":"[The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].","finding":"","journal":"Gan to kagaku ryoho. Cancer & chemotherapy","studyType":"Clinical Study"},{"pmid":"16352947","year":"2005","title":"[CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].","finding":"","journal":"Gan to kagaku ryoho. Cancer & chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"indisetron","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 3A","category":"target"},{"label":"HTR3A","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"sinseron","offLabel":[],"synonyms":["indisetron hydrochloride","indisetron HCl","sinseron","indisetron"],"timeline":[],"aiSummary":"Sinseron (INDISETRON) is a small molecule drug that targets the 5-hydroxytryptamine receptor 3A. It is classified as an indisetron and works by modulating serotonin receptors in the body. However, due to the lack of available information, its commercial status, approved indications, and key safety considerations are unknown. Further research is needed to determine its potential as a therapeutic agent. As a result, its current status in the pharmaceutical market remains unclear.","approvals":[],"brandName":"Sinseron","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 3A","targets":[{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"}],"modality":"Small Molecule","drugClass":"indisetron","explanation":"Imagine your brain has a special messenger system that uses serotonin to send signals. Sinseron helps regulate this system by blocking or enhancing the activity of serotonin receptors, which can affect mood, appetite, and other functions. By doing so, it may help alleviate symptoms associated with certain conditions.","oneSentence":"Sinseron works by binding to the 5-hydroxytryptamine receptor 3A, which is involved in various physiological processes.","technicalDetail":"Sinseron acts as a selective antagonist at the 5-HT3A receptor, a subtype of serotonin receptor that plays a crucial role in the regulation of neurotransmitter release and synaptic plasticity."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Indisetron","title":"Indisetron","extract":"Indisetron is a drug used for prophylaxis of chemotherapy-induced nausea and vomiting. It was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2004."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1438","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INDISETRON","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Indisetron","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T12:04:13.818059","biosimilars":[],"competitors":[{"drugName":"alosetron","drugSlug":"alosetron","fdaApproval":"2000-02-09","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"bupivacaine","drugSlug":"bupivacaine","fdaApproval":"1972-10-03","patentExpiry":"Mar 17, 2042","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"clozapine","drugSlug":"clozapine","fdaApproval":"1989-09-26","patentExpiry":"May 1, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"diltiazem","drugSlug":"diltiazem","fdaApproval":"1982-11-05","genericCount":38,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dolasetron","drugSlug":"dolasetron","fdaApproval":"1997-09-11","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"indisetron","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alosetron","brandName":"alosetron","genericName":"alosetron","approvalYear":"2000","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"bupivacaine","brandName":"bupivacaine","genericName":"bupivacaine","approvalYear":"1972","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"},{"drugId":"clozapine","brandName":"clozapine","genericName":"clozapine","approvalYear":"1989","relationship":"same-target"},{"drugId":"diltiazem","brandName":"diltiazem","genericName":"diltiazem","approvalYear":"1982","relationship":"same-target"},{"drugId":"dolasetron","brandName":"dolasetron","genericName":"dolasetron","approvalYear":"1997","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"89RBZ66NVC","CHEBI":"CHEBI:135344","INN_ID":"7551","UMLSCUI":"C2825324","ChEMBL_ID":"CHEMBL2104994","KEGG_DRUG":"1438","PUBCHEM_CID":"178039","SECONDARY_CAS_RN":"160472-97-9","MESH_SUPPLEMENTAL_RECORD_UI":"C500220"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"66%"},"publicationCount":7,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2012","pmid":"23364217","title":"Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.","journal":"Chemotherapy"},{"date":"2009 Dec","pmid":"19967488","title":"Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists.","journal":"International journal of clinical oncology"},{"date":"2009 Sep","pmid":"19755818","title":"[The efficacy of indisetron hydrochloride for the management of chemotherapy-induced nausea and vomiting for lung cancer].","journal":"Gan to kagaku ryoho. Cancer & chemotherapy"},{"date":"2008 Jul","pmid":"18633256","title":"[The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].","journal":"Gan to kagaku ryoho. Cancer & chemotherapy"},{"date":"2005 Dec","pmid":"16352947","title":"[CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].","journal":"Gan to kagaku ryoho. Cancer & chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}